NEW YORK – January 11, 2025 (NEWMEDIAWIRE) – Kaplan Fox & Kilsheimer LLP pronounces {that a} class motion lawsuit has been filed towards Revance Therapeutics (NASDAQ:), Inc. (Revance or the Firm) (NASDAQ: RVNC) on behalf of traders that bought or in any other case acquired Revance securities between February 29, 2024 and December 6, 2024 (the Class Interval).
CLICK HERE TO JOIN THE CASE
In case you are an investor in Revance and have suffered losses, you might CLICK HERE to contact us. You may additionally contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.
DEADLINE REMINDER: In case you are a member of the proposed Class, you might transfer the court docket no later than March 4, 2025 to function a lead plaintiff for the purported class. In case you have losses we encourage you to contact us to study extra in regards to the lead plaintiff course of.
Revance is a biotechnology firm and the distributor of sure dermal filler merchandise pursuant to an unique distribution settlement with Teoxane SA.
On August 12, 2024, Revance issued a press launch asserting that the Firm had entered right into a merger settlement with Crown Laboratories (Crown). Below the phrases of the settlement, the press launch indicated that Crown would begin a young supply to accumulate all excellent shares of Revances frequent inventory for $6.66 per share (the Tender Provide).
Then, on September 23, 2024, Revance disclosed that it obtained a discover to treatment alleged materials breaches, together with breaches of the utmost ranges of buffer inventory and required efforts to advertise and promote Teoxane merchandise, beneath the Companys unique distribution settlement with Teoxane SA. As a result of dispute with Teoxane, the Firm suggested that Crowns Tender Provide had been delayed till a minimum of October 4, 2024.
On this information, the worth of Revance inventory fell $.445 per share, or 7.66%, to shut at $5.365 per share on September 23, 2024.
Then, on December 9, 2024, the Firm disclosed that Crown and Revance had amended their merger settlement, and that Crown would begin a young supply on December 12, 2024 to accumulate all excellent shares of Revance frequent inventory for $3.10 per share, greater than 50% decrease than the unique buy value.
On this information, the worth of Revance inventory fell $.79 per share, or 20.68%, to shut at $3.03 per share on December 9, 2024.
The criticism alleges, amongst different issues, that all through the Class Interval, Defendants made false and/or deceptive statements and/or did not disclose that (i) Revance was in materials breach of the Distribution Settlement; (ii) the foregoing subjected the Firm to an elevated danger of litigation, in addition to financial and reputational hurt; and (iii) all of the foregoing elevated the danger that the Tender Provide could be delayed and/or amended.
WHY CONTACT KAPLAN FOX – Kaplan Fox is a number one nationwide regulation agency specializing in complicated litigation with workplaces in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of expertise in securities litigation, Kaplan Fox affords the skilled expertise and monitor document that purchasers demand. By means of prosecuting instances on the federal and state ranges, Kaplan Fox has efficiently formed the regulation by successful many essential selections on behalf of our purchasers. For extra details about Kaplan Fox & Kilsheimer LLP, you might go to our web site at www.kaplanfox.com .
This press launch could also be thought of Lawyer Promoting in some jurisdictions beneath the relevant regulation and moral guidelines.
In case you have any questions on this Discover, your rights, or your pursuits, please contact:
CONTACT:
Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, thirty eighth Ground
New York, New York 10022
(646) 315-9003
pmayer@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Avenue, Suite 1560
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com
View the unique launch on www.newmediawire.com
Copyright 2025 JCN Newswire . All rights reserved.
